Peter Cancelmo Sells 25,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of Omeros stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $18.65, for a total value of $466,250.00. Following the completion of the transaction, the vice president owned 200 shares of the company’s stock, valued at approximately $3,730. This represents a 99.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Omeros Price Performance

OMER stock traded down $0.04 during mid-day trading on Tuesday, reaching $18.75. 2,042,181 shares of the company’s stock were exchanged, compared to its average volume of 1,711,567. The company has a market cap of $1.36 billion, a price-to-earnings ratio of 14.65 and a beta of 2.54. The stock’s 50 day moving average is $12.81 and its 200 day moving average is $12.08. Omeros Corporation has a 12-month low of $3.94 and a 12-month high of $19.65.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, research analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on OMER. HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Institutional Trading of Omeros

A number of institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new position in Omeros in the 1st quarter valued at $357,000. XTX Topco Ltd acquired a new stake in shares of Omeros in the second quarter valued at about $191,000. Invesco Ltd. raised its position in shares of Omeros by 34.1% in the second quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 29,644 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Omeros by 15.1% in the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock worth $2,224,000 after buying an additional 97,224 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in shares of Omeros in the second quarter worth about $40,000. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.